newsfilter
← Latest News
Business Wire·

Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

Recruitment of the pivotal Phase 3 LUCIDITY trial of avexitide in PBH is complete; continue to expect to randomize and dose last eligible participants in Q1 2026, with topline data anticipated in Q3 2026 Cash runway